ArticleScientific reports2026
Leishmanicidal efficacy of cold atmospheric multiple plasma jet against Leishmania major in a murine model: effects on parasite burden, cytokine profiles, and wound healing.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cutaneous leishmaniasis (CL) is a neglected tropical disease with limited effective treatments options due to drug toxicity, emerging resistance, and complex therapeutic regimens. The Cold Atmospheric Multiple Plasma Jet (CAMPJ) has recently gained attention as a novel therapeutic modality because it generates reactive oxygen and nitrogen species, with antimicrobial and immunomodulatory activity. This study evaluates the therapeutic efficacy of CAMPJ in a BALB/c mouse model of CL, focusing on its leishmanicidal, wound-healing, and immunomodulatory effects. Female BALB/c mice were inoculated with Leishmania major promastigotes and, after lesion development, assigned to six groups: topical amphotericin B (positive control), CAMPJ (treatment for 5, 10, or 15) minutes, untreated control, and air-treated control. CAMPJ and control treatments were administered twice a week for 21 days, while amphotericin B was applied daily. Lesion progression was monitored weekly using Digitizer software, parasite burden was quantified via Leishman-Donovan Units (LDU), and cytokine levels (IFN-γ and IL-4) were measured by ELISA. CAMPJ treatment produced a significant reduction in lesion size compared with negative controls (p < 0.05), with the 15-minute exposure yielding the greatest improvement. Splenic parasite burden decreased significantly across all CAMPJ-treated groups, again with the 15 min group showing the lowest LDU values. Notably, 15 min CAMPJ exposure promoted a Th1-biased immune response, characterized by elevated IFN-γ and reduced IL-4 contrasting with the Th2 dominant profile observed in untreated controls. These findings indicate that CAMPJ exhibits strong leishmanicidal activity and beneficial immunomodulatory effects, supporting its potential as an alternative or adjunct therapy for CL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.